As Biotechnology companies, Aimmune Therapeutics Inc. (NASDAQ:AIMT) and Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) are our subject to compare. And more specifically their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aimmune Therapeutics Inc. | 21 | 0.00 | N/A | -3.62 | 0.00 |
| Kiniksa Pharmaceuticals Ltd. | 15 | 0.00 | N/A | -3.03 | 0.00 |
Demonstrates Aimmune Therapeutics Inc. and Kiniksa Pharmaceuticals Ltd. earnings per share, top-line revenue and valuation.
Profitability
Table 2 shows Aimmune Therapeutics Inc. and Kiniksa Pharmaceuticals Ltd.’s return on equity, return on assets and net margins.
| Net Margins | Return on Equity | Return on Assets | |
| Aimmune Therapeutics Inc. | 0.00% | -79.1% | -66.4% |
| Kiniksa Pharmaceuticals Ltd. | 0.00% | -49.1% | -44.4% |
Liquidity
Aimmune Therapeutics Inc.’s Current Ratio and Quick Ratio are 7.6 and 7.6 respectively. The Current Ratio and Quick Ratio of its competitor Kiniksa Pharmaceuticals Ltd. are 9.1 and 9.1 respectively. Kiniksa Pharmaceuticals Ltd. therefore has a better chance of paying off short and long-term obligations compared to Aimmune Therapeutics Inc.
Analyst Recommendations
Ratings and Recommendations for Aimmune Therapeutics Inc. and Kiniksa Pharmaceuticals Ltd. can be find in next table.
| Sell Ratings | Hold Ratings | Buy Ratings | Rating Score | |
| Aimmune Therapeutics Inc. | 0 | 0 | 0 | 0.00 |
| Kiniksa Pharmaceuticals Ltd. | 0 | 0 | 2 | 3.00 |
$36 is Aimmune Therapeutics Inc.’s consensus target price while its potential upside is 60.50%. Competitively Kiniksa Pharmaceuticals Ltd. has an average target price of $30.5, with potential upside of 205.31%. The results from earlier shows that analysts belief suggest that Kiniksa Pharmaceuticals Ltd. seems more appealing than Aimmune Therapeutics Inc.
Insider & Institutional Ownership
Institutional investors held 86.3% of Aimmune Therapeutics Inc. shares and 85.5% of Kiniksa Pharmaceuticals Ltd. shares. 0.6% are Aimmune Therapeutics Inc.’s share held by insiders. Comparatively, insiders own roughly 0.1% of Kiniksa Pharmaceuticals Ltd.’s shares.
Performance
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
| Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
| Aimmune Therapeutics Inc. | 1.91% | -9.03% | -2.92% | -15.79% | -29.77% | -19.52% |
| Kiniksa Pharmaceuticals Ltd. | -9.51% | -11.61% | -17.6% | -35.38% | -12.2% | -57.99% |
For the past year Aimmune Therapeutics Inc. was less bearish than Kiniksa Pharmaceuticals Ltd.
Summary
Kiniksa Pharmaceuticals Ltd. beats Aimmune Therapeutics Inc. on 6 of the 8 factors.
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. The company was founded in 2011 and is headquartered in Brisbane, California.
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
